Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why I remain bullish on IMNM stock.
The fate of the Chinese-owned app is uncertain, but the effects of banning it would ripple through campus communities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback